PIL seeks curbs on antibiotics sale without prescription

A Mumbai-based lawyer has filed a public interest litigation (PIL) before the Bombay High Court seeking a directive to restrict over-the-counter sale of antibiotics in India, the world’s “largest consumer of antibiotics”.
The petition followed investigation by an activist who found that antibiotics under ‘restricted use’ were freely available over the counter across pharmacies in India.
The PIL pointed to the United Nations high-level meeting on antimicrobial resistance and said a UN declaration had asked countries to come up with an action plan to curb the misuse of antibiotics by 2018. “That the pressure is on India, the world’s largest consumer of antibiotics and where carelessness in antibiotic use and environmental antibiotic pollution has been documented,” the petition said.
Antibiotic drugs are part of a nearly Rs. 17,000-crore business in India, growing at 5-6% annually. India is one of the biggest consumers of antibiotics. These drugs are also used rampantly in agriculture, specifically for poultry and livestock.
Looking for chemical products? Let suppliers reach out to you!
2026-07-13
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
The GLP-1 Sweet Shot in India’s Diabetic Gut
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
India Targets Fake Drug Packaging
Recommend Reading
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Sandoz Set to Slash Canadian Weight-loss Drug Prices by Up to 70 Percent Generics Could Expand Patient Access
-
Formic Acid Prices Stabilize After Declining Post-Holiday
-
Mitsui, Idemitsu, and Sumitomo Restructure Polyolefins Business
-
Sinopec H1 Net Profit Plunges 44 Percent to 21.6 Billion Yuan Despite Output Growth Chemical Margins Remain Under Pressure
-
China’s Acetone Market in 2025 Continues to Decline, Constantly Reaching New Lows
-
Double Positive Factors for Costs and Supply—PTA Prices Show Volatile but Strong Tendencies